🇺🇸 Oliver Sartor, MD

Distinguished Investigators

🇺🇸 United States

Andrei Iagaru, MD Andrew Armstrong, MD Daniel P. Petrylak, MD Geoffrey Johnson, MD Ghassan El-Haddad, MD Jeff Michalski, MD Jeremie Calais, MD, PhD Luke T. Nordquist, MD Michael Gorin, MD Michael J. Morris, MD, PhD Neal Shore, MD Neeraj Agarwal, MD Oliver Sartor, MD Scott Tagawa, MD

🇫🇷 France

Karim Fizazi, MD, PhD

🇨🇦 Canada

Kim Chi, MD

🇬🇧 United Kingdom

Professor Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD, FMedSci

🇩🇪 Germany

Professor Ken Herrmann, MD

🇦🇺 Australia

Professor Louise Emmett, MBChB, FRACP, FAANMS, MD

Oliver Sartor, MD

Dr. Oliver Sartor is an internationally recognized expert in prostate cancer. His medical practice and research have focused on prostate cancer since 1990 when he finished a medical oncology fellowship at the National Cancer Institute (NCI). He has published over 400 peer-reviewed articles, led or co-led multiple national and international clinical studies, including three radiopharmaceutical phase III studies pivotal for FDA approval in prostate cancer (Samarium-153 EDTMP, Radium-223, and Lu-177-PSMA-617). He has lectured widely, and at last count has given invited lectures in 33 countries. He is currently the Associate Dean for Oncology, Medical Director of the Tulane Cancer Center, and serves as the Laborde Professor for Cancer Research at Tulane Medical School with appointments in both the Medicine and Urology Departments. He is the Medical Oncology Chair of the GU committee of NRG, a national cancer research group. He is also a past member of the National Cancer Institute Board of Scientific Counselors (Clinical Sciences and Epidemiology).